DOI: https://doi.org/10.14710/jbtr.v12i1.29335

Prevalence and Antibiotic Susceptibility Pattern of Multidrug-Resistant Pseudomonas aeruginosa in a Tertiary Hospital, South Sumatera, Indonesia

1Faculty of Medicine, Universitas Sriwijaya, Indonesia

2Department of Microbiology, Universitas Sriwijaya, Indonesia

31. Department of Microbiology, Universitas Sriwijaya, Indonesia

4 2. Clinical Microbiology Laboratory Installation, RSUP Dr. Mohammad Hoesin, Indonesia

View all affiliations
Received: 10 Sep 2025; Revised: 4 Feb 2026; Accepted: 26 Feb 2026; Available online: 29 Apr 2026; Published: 30 Apr 2026.
Open Access Copyright (c) 2026 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

ABSTRACT

Background: Pseudomonas aeruginosa is a Gram-negative bacterium that causes opportunistic and healthcare-acquired infections. Its ability to rapidly acquire antibiotic resistance complicates treatment, prolongs hospitalization, and increases morbidity, mortality, and healthcare costs.

Objective: This study aimed to determine the prevalence and antibiotic susceptibility pattern of multidrug-resistant P. aeruginosa at Dr. Mohammad Hoesin General Hospital, South Sumatera, Indonesia.

Methods: A descriptive observational study with a cross-sectional design was conducted using data from the Clinical Microbiology Laboratory and Medical Records Installation of Dr. Mohammad Hoesin General Hospital, Palembang, from May 2022 to April 2023. Data were analyzed univariately and presented through tables, figures, and descriptive summaries.

Results: A total of 465 hospitalized patients were found to be infected with P. aeruginosa. Adult patients aged 18–65 years were the most affected (71%). The leading primary diagnoses were diabetic foot ulcer, pneumonia, and sepsis. Most patients were hospitalized for 8–14 days (25.2%). Antibiotic susceptibility testing showed the highest sensitivity to amikacin (94.2%), while the lowest was observed with meropenem and ceftazidime. The resistance profile included 24.7% MDR, 6.7% XDR, 0.9% probable PDR, and 2.4% DTR isolates.

Conclusion: P. aeruginosa infections were predominantly found in adult patients with prolonged hospitalization. Amikacin remains the most effective antibiotic, while cefazolin and tigecycline showed poor efficacy. The presence of MDR, XDR, PDR, and DTR strains highlights the urgent need for rational antibiotic use and strengthened antimicrobial stewardship programs.

 

Keywords:

Pseudomonas aeruginosa, Hospitalized patients, Antibiotic resistance, Multidrug resistance

Note: This article has supplementary file(s).

Fulltext View|Download |  Cover Letter
Letter to the Editor
Subject
Type Cover Letter
  Download (51KB)    Indexing metadata
 Transcripts
Short Communication
Subject
Type Transcripts
  Download (4MB)    Indexing metadata
 Research Instrument
Copyright Transfer Agreement (CTA)
Subject
Type Research Instrument
  Download (463KB)    Indexing metadata
Email colleagues
Keywords: Pseudomonas aeruginosa; hospitalized patients; antibiotic resistance; multidrug resistance

Article Metrics:

Article Info
Section: Original Research Articles
Language : EN
  1. REFERENCES
  2. Moradali MF, Ghods S, Rehm BHA. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Vol. 7, Frontiers in Cellular and Infection Microbiology. Gainesville: University of Florida; 2017. p. 39. Available from: https://doi.org/10.3389/fcimb.2017.00039
  3. Rezzoagli C, Granato ET, Kümmerli R. Harnessing Bacterial Interactions to Manage Infections: A Review on the Opportunistic Pathogen Pseudomonas aeruginosa as A Case Example. Vol. 69, Journal of Medical Microbiology. Oxford: Microbiology Society; 2020. p. 147–61. Available from: https://doi.org/10.1099/jmm.0.001134
  4. Riedel S, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, et al. Jawetz, Melnick, & Adelberg’s Medical Microbiology. 28th ed. New York: McGraw-Hill Education; 2019
  5. Sauvage S, Hardouin J. Exoproteomics for Better Understanding Pseudomonas aeruginosa Virulence. Vol. 12, Toxins. Mont-Saint-Aignan: MDPI; 2020. p. 571. Available from: https://doi.org/10.3390/toxins12090571
  6. Laudy AE, Róg P, Smolinska-Król K, Ćmiel M, Søoczynska A, Patzer J, et al. Prevalence of ESBL-Producing Pseudomonas aeruginosa Isolates in Warsaw, Poland, Detected by Various Phenotypic and Genotypic Methods. PLoS ONE. 2017 Jun 1;12(6):1–15. Available from: https://dx.doi.org/10.1371/journal.pone.0180121
  7. Jouault A, Saliba AM, Touqui L. Modulation of the Immune Response by the Pseudomonas aeruginosa Type-III Secretion System. Frontiers in cellular and infection microbiology. 2022;12:1064010. Available from: https://doi.org/10.3389/fcimb.2022.1064010
  8. Žiemytė M, Carda-Diéguez M, Rodríguez-Díaz JC, Ventero MP, Mira A, Ferrer MD. Real-Time Monitoring of Pseudomonas aeruginosa Biofilm Growth Dynamics and Persister Cells’ Eradication. Emerging Microbes and Infections. 2021;10(1):2062–75. Available from: https://dx.doi.org/10.1080/22221751.2021.1994355
  9. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic Resistance in Pseudomonas aeruginosa: Mechanisms and Alternative Therapeutic Strategies. Biotechnology Advances. 2019;37(1):177–92. Available from: https://doi.org/10.1016/j.biotechadv.2018.11.013
  10. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews. 2019 Sep;32(4). Available from: https://doi.org/10.1128/CMR.00031-19
  11. Thi MTT, Wibowo D, Rehm BHA. Pseudomonas aeruginosa Biofilms. Vol. 21, International Journal of Molecular Sciences. Nathan: Griffith University; 2020. p. 1–25. Available from: https://doi.org/10.3390/ijms21228671
  12. Behzadi P, Baráth Z, Gajdács M. It’s Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa. Vol. 10, Antibiotics. 2021
  13. Wisdom Nzubechukwu Obiefu, Nnaemeka Jireh Okolie, Chizaram Winners Ndubueze, Joy Nkeiruka Dike-Ndudim. Antibacterial Effect of Chromolaena odorata (Awolowo Leaf) Aqueous Leaf Extract on Pseudomonas aeruginosa Induced Gastrointestinal Tract Infection in Adult Wistar Rat. GSC Biological and Pharmaceutical Sciences. 2021 Jan 30;14(1):055–64. Available from: https://doi.org/10.30574/gscbps.2021.14.1.0006
  14. CDC. About Pseudomonas aeruginosa. Centers for Disease Control and Prevention (CDC). 2025 [cited 2023 Jun 12]. Available from: https://www.cdc.gov/pseudomonas-aeruginosa/about/
  15. Sutrisno VS. Prevalensi dan Pola Sensitivitas Basil Gram-Negatif Multidrug Resistant (MDR) di RSUP Dr. Mohammad Hoesin Palembang. Palembang; 2020
  16. Pratiwi RH. Mekanisme Pertahanan Bakteri Patogen terhadap Antibiotik. Jurnal Pro Life. 2017;4(3):418–29. Available from: https://doi.org/10.33541/jpvol6Iss2pp102
  17. Chai YH, Xu JF. How Does Pseudomonas aeruginosa Affect the Progression of Bronchiectasis?. Vol. 26, Clinical Microbiology and Infection. Shanghai: Elsevier B.V.; 2020. p. 313–8. Available from: https://dx.doi.org/10.1016/j.cmi.2019.07.010
  18. Kuntaman, Karuniawati A, Gunardi W, Anggaini D, Santosaningsih D, Saptawati L, et al. Surveilans Resistansi Antibiotik Rumah Sakit di Indonesia Tahun 2021. Jakarta: Perhimpunan Dokter Spesialis Mikrobiologi Klinik Indonesia (PAMKI); 2022
  19. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. Washington: Clinical and Laboratory Standards Institute; 2022
  20. Alkofide H, Alhammad AM, Alruwaili A, Aldemerdash A, Almangour TA, Alsuwayegh A, et al. Multidrug-Resistant and Extensively Drug-Resistant Enterobacteriaceae: Prevalence, Treatments, and Outcomes - A Retrospective Cohort Study. Infection and Drug Resistance. 2020;13:4653–62. Available from: https://doi.org/10.2147/IDR.S283488
  21. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR). Clinical Infectious Diseases. 2022;75(2):187–212. Available from: https://doi.org/10.1093/cid/ciac268
  22. Primasari FS, Puspitasari I, Nuryastuti T. Prevalensi Bakteri Resisten Karbapenem di RSUP Dr. Sardjito Periode Januari-Agustus 2020. Majalah Farmaseutik. 2022;18(3):265–71. Available from: https://doi.org/10.22146/farmaseutik.v18i3.65823
  23. Dharmayanti IGAMP, Sukrama DM. Karakteristik Bakteri Pseudomonas aeruginosa dan Pola Kepekaannya terhadap Antibiotik di Intensive Care Unit (ICU) RSUP Sanglah pada Bulan November 2014 – Januari 2015. E-Journal Medika. 2019;8(4):1–9. Available from: https://doi.org/10.1002/9781119009924.eopr0398
  24. Fabian P, Alimsardjono L, Indiastuti DN. Pola Resistensi Bakteri Pseudomonas aeruginosa dan Acinetobacter baumannii pada Spesimen Darah terhadap Antibiotik Golongan β-laktam dan Aminoglikosida di RSUD Dr. Soetomo periode Januari 2016 – Desember 2016. Jurnal Kedokteran Syiah Kuala. 2020;20(1):31–6. Available from: https://doi.org/10.24815/jks.v20i1.18296
  25. Hosu MC, Vasaikar SD, Okuthe GE, Apalata T. Detection of Extended Spectrum Beta-Lactamase Genes in Pseudomonas aeruginosa Isolated from Patients in Rural Eastern Cape Province, South Africa. Scientific Reports. 2021;11(1):7110. Available from: https://doi.org/10.1038/s41598-021-86570-y
  26. Zhang Y, Li Y, Zeng J, Chang Y, Han S, Zhao J, et al. Risk Factors for Mortality of Inpatients with Pseudomonas aeruginosa Bacteremia in China: Impact of Resistance Profile in the Mortality. Infection and drug resistance. 2020;13:4115–23. Available from: https://doi.org/10.2147/IDR.S268744
  27. Motbainor H, Bereded F, Mulu W. Multi-drug Resistance of Blood Stream, Urinary Tract and Surgical Site Nosocomial Infections of Acinetobacter baumannii and Pseudomonas aeruginosa among Patients Hospitalized at Felegehiwot Referral Hospital, Northwest Ethiopia: A Cross-Sectional Study. BMC Infectious Diseases. 2020;20(1):92. Available from: https://doi.org/10.1186/s12879-020-4811-8
  28. Gill JS, Arora S, Khanna SP, Kumar KH. Prevalence of Multidrug-resistant, Extensively Drug-resistant, and Pandrug-resistant Pseudomonas aeruginosa from a Tertiary Level Intensive Care Unit. Journal of Global iIfectious Diseases. 2016;8(4):155–9. Available from: https://doi.org/10.4103/0974-777X.192962
  29. El Chakhtoura NG, Bonomo RA, Jump RLP. Influence of Aging and Environment on Presentation of Infection in Older Adults. Infectious disease clinics of North America. 2017 Dec;31(4):593–608. Available from: https://doi.org/10.1016/j.idc.2017.07.017
  30. Martín S, Pérez A, Aldecoa C. Sepsis and Immunosenescence in the Elderly Patient: A Review. Frontiers in medicine. 2017;4:20. Available from: https://doi.org/10.3389/fmed.2017.00020
  31. Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, et al. Risk Factors for Mortality Among Patients with Pseudomonas aeruginosa Bacteraemia: A Retrospective Multicentre Study. International journal of antimicrobial agents. 2020 Feb;55(2):105847. Available from: https://doi.org/10.1016/j.ijantimicag.2019.11.004
  32. Kristiningrum S, Widyawati IY, Huda N. Identifikasi Infeksi Multidrug Resistant Organism (MDRO) pada Pasien ICU. Vol. 5, Journal of Telenursing (JOTING). 2023. p. 180–9. Available from: https://doi.org/10.31539/joting.v5i1.5404
  33. Nair V, Sahni AK, Sharma D, Grover N, Shankar S, Chakravarty A, et al. Point Prevalence and Risk Factor Assessment for Hospital-Acquired Infections in A Tertiary Care Hospital in Pune, India. The Indian journal of medical research. 2017 Jun;145(6):824–32. Available from: https://doi.org/10.4103/ijmr.ijmr_1167_15
  34. Deni J, Pangalila JF. Hubungan Keberhasilan Terapi Pneumonia Nosokomial Resisten Pseudmonas aeruginosa dan Acinetobacter baumannii dengan Dosis Karbapenem Di ICU RS Royal Taruma Periode 2012-2017. Vol. 1, Tarumanegara Medical Journal. 2019. p. 532–43. Available from: https://doi.org/10.24912/tmj.v2i1.5865
  35. Monegro AF, Muppidi V, Regunath H. Hospital-Acquired Infections. StatPearls. 2023; Available from: http://www.ncbi.nlm.nih.gov/books/nbk441857/
  36. Li Y, Wang Z, Tan L, Liang L, Liu S, Huang J, et al. Hospitalization, Case Fatality, Comorbidities, and Isolated Pathogens of Adult Inpatients with Pneumonia from 2013 to 2022: A Real-World Study in Guangzhou, China. BMC Infectious Diseases. 2024;24(1):2. Available from: https://doi.org/10.1186/s12879-023-08929-y
  37. Estiningsih D, Puspitasari I, Nuryastuti T. Identifikasi Infeksi Multidrug-Resistant Organisms (MDRO) pada Pasien yang Dirawat di Bangsal Neonatal Intensive Care Unit (NICU) Rumah Sakit. Jurnal Manajemen dan Pelayanan Farmasi. 2016;6(3):1–6. Available from: http://dx.doi.org/10.22146/jmpf.351
  38. Wijaksana DS, Anggraeni N, Endriani R. Pola Bakteri dan Resistensi Antibiotik pada Pasien Sepsis di Intensive Care Unit (ICU) RSUD Arifin Achmad Provinsi Riau Periode 1 Januari – 31 Desember 2017. Vol. 13, Jurnal Ilmu Kedokteran. 2019. p. 46. Available from: https://doi.org/10.26891/jik.v13i2.2019.46-54
  39. Farras Aziz F, Suryadinata H, Wahyudi K. Pola Bakteri Pasien Rawat Inap Pneumonia Komunitas Dewasa Rumah Sakit Hasan Sadikin Bandung Tahun 2018. Indonesia Journal Chest. 2020;7(2):8–17
  40. Hardia L, Djide MN, Arief M, Kunci K. Deteksi Fenotip Isolat Pseudomonas aeruginosa Penghasil Mettalo Beta-Laktamase (MBL) Resisten Karbapenem pada Pasien Infeksi di RSUP Dr. Wahidin Sudirohusodo Makassar. Majalah Farmasi dan Farmakologi. 2022;26(2):48–51. Available from: https://doi.org/10.20956/mff.v26i2.17871
  41. Coello Pelegrin A, Palmieri M, Mirande-Meunier C, Oliver A, Moons P, Goossens H, et al. Pseudomonas aeruginosa: A Clinical and Genomics Update. FEMS microbiology reviews. 2021 May 10;45. Available from: https://doi.org/10.1093/femsre/fuab026
  42. Garousi M, MonazamiTabar S, Mirazi H, Farrokhi Z, Khaledi A, Shakerimoghaddam A. Epidemiology of Pseudomonas aeruginosa in Diabetic Foot Infections: A Global Systematic Review and Meta-Analysis. Germs. 2023 Dec;13(4):362–72. Available from: https://doi.org/10.18683/germs.2023.1406
  43. Spagnolo AM, Sartini M, Cristina ML. Pseudomonas aeruginosa in the Healthcare Facility Setting. Reviews and Research in Medical Microbiology. 2021;32(3). Available from: https://doi.org/10.1097/MRM.0000000000000271
  44. CDC. What is Sepsis?. U.S. Centers for Disease Control and Prevention. 2023 [cited 2023 Jun 12]. Available from: https://www.cdc.gov/sepsis/what-is-sepsis.html
  45. Saputra IPGS, Iswari IS, Pinatih KJP. Prevalensi dan Pola Kepekaan Multidrug Resistance Pseudomonas aeruginosa terhadap Antibiotika pada Pasien Pneumonia di RSUP Sanglah. Jurnal Medika Udayana. 2021;10(12):89–95. Available from: https://doi.org/10.24843.MU.2021.V10.i12.P15
  46. Reynolds D, Kollef M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs. 2021;81(18):2117–31. Available from: https://doi.org/10.1007/s40265-021-01635-6
  47. Valentini M, Gonzalez D, Mavridou DA, Filloux A. Lifestyle Transitions and Adaptive Pathogenesis of Pseudomonas aeruginosa. Vol. 41, Current Opinion in Microbiology. Lausanne: Elsevier Ltd; 2018. p. 15–20. Available from: https://dx.doi.org/10.1016/j.mib.2017.11.006
  48. Anggraini D, Yulindra UG, Savira M. Prevalensi dan Pola Sensitivitas Antimikroba Multidrug Resistant Pseudomonas aeruginosa di RSUD Arifin Achmad. Vol. 50, Majalah Kedokteran Bandung. 2018. p. 6–12. Available from: http://dx.doi.org/10.15395/mkb.v50n1.1150
  49. Pérez A, Gato E, Pérez-Llarena J, Fernández-Cuenca F, Gude MJ, Oviaño M, et al. High Incidence of MDR and XDR Pseudomonas aeruginosa Isolates Obtained from Patients with Ventilator-Associated Pneumonia in Greece, Italy and Spain as Part of the MagicBullet Clinical Trial. The Journal of antimicrobial chemotherapy. 2019 May;74(5):1244–52. Available from: https://doi.org/10.1093/jac/dkz030
  50. Oliver A, Rojo-Molinero E, Arca-Suarez J, Beşli Y, Bogaerts P, Cantón R, et al. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clinical Microbiology and Infection. 2024;30(4):469–80. Available from: https://doi.org/10.1016/j.cmi.2023.12.026
  51. Saeli N, Jafari-Ramedani S, Ramazanzadeh R, Nazari M, Sahebkar A, Khademi F. Prevalence and mechanisms of aminoglycoside resistance among drug-resistant Pseudomonas aeruginosa clinical isolates in Iran. BMC Infectious Diseases. 2024;24(1):680. Available from: https://doi.org/10.1186/s12879-024-09585-6
  52. Elfadadny A, Ragab RF, AlHarbi M, Badshah F, Ibáñez-Arancibia E, Farag A, et al. Antimicrobial Resistance of Pseudomonas aeruginosa: Navigating Clinical Impacts, Current Resistance Trends, and Innovations in Breaking Therapies. Frontiers in Microbiology. 2024;Volume 15. Available from: https://doi.org/10.3389/fmicb.2024.1374466
  53. Arabameri N, Heshmatipour Z, Eftekhar Ardebili S, Jafari Bidhendi Z. The Role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas aeruginosa. Iranian Journal of Pathology. 2021;16(4):426–32. Available from: https://doi.org/10.30699/IJP.2021.520570.2542
  54. Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. Antimicrobial agents and chemotherapy. 2018 Dec;62(12). Available from: https://doi.org/10.1128/AAC.01587-18
  55. Ramatla T, Nkhebenyane J, Lekota KE, Thekisoe O, Monyama M, Achilonu CC, et al. Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeruginosa reported from 2014 to 2024: a systematic review and meta-analysis. Frontiers in microbiology. 2025;16:1599070. Available from: https://doi.org/10.3389/fmicb.2025.1599070
  56. El Menofy NG, Tawfick MM, Badawy MSEM. Molecular study of carbapenem-resistant Pseudomonas aeruginosa causing wound infection in an Egyptian tertiary hospital. Journal of infection in developing countries. 2025 Jul;19(7):997–1006. Available from: https://doi.org/10.3855/jidc.19953
  57. Gach MW, Lazarus G, Simadibrata DM, Sinto R, Saharman YR, Limato R, et al. Antimicrobial resistance among common bacterial pathogens in Indonesia: a systematic review. The Lancet regional health Southeast Asia. 2024 Jul;26:100414. Available from: https://doi.org/10.1016/j.lansea.2024.100414
  58. Lameng I, Budayanti N, Prilandari L, Adhiputra I. Antimicrobial Resistance Profile of MDR & Non-MDR Meropenem-Resistant Pseudomonas aeruginosa Isolates of Patients in Intensive Care Unit of Tertiary Hospital. Indonesian Journal of Tropical and Infectious Disease. 2021 Dec 27;9:152. Available from: https://doi.org/10.20473/ijtid.v9i3.30000
  59. Diah Lestari, Husyain Djajaningrat, Febri Wulan Dari, Dean Handimulya. Sensitivitas Antara Antibiotik Meropenem dan Seftazidin Terhadap Pseudomonas aeruginosa Strain ATCC 15442 Pada Pasien Pneumonia di RSUP dr. Cipto Mangunkusumo Jakarta Pusat. Anakes: Jurnal Ilmiah Analis Kesehatan. 2025 Mar 30;11(1 SE-Articles):1–9. Available from: https://doi.org/10.37012/anakes.v11i1.2500
  60. Uyar NY, Ayaş M, Kocagöz AS. Antibiotic resistance profile of Pseudomonas aeruginosa strains isolated from blood culture of patients in intensive care units. Journal of Critical Care. 2024;81:154709. Available from: https://doi.org/10.1016/j.jcrc.2024.154709
  61. Diorio-Toth L, Irum S, Potter RF, Wallace MA, Arslan M, Munir T, et al. Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance. Microbiology spectrum. 2022 Jun;10(3):e0076622. Available from: https://doi.org/10.1128/spectrum.00766-22
  62. Valzano F, La Bella G, Lopizzo T, Curci A, Lupo L, Morelli E, et al. Resistance to ceftazidime-avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study. Microbiology Spectrum. 2024 Aug;12(8):e0426623. Available from: https://doi.org/10.1128/spectrum.04266-23
  63. Santoro A, Franceschini E, Meschiari M, Menozzi M, Zona S, Venturelli C, et al. Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria. Open Forum Infectious Diseases. 2020 Nov 1;7(11):ofaa461. Available from: https://doi.org/10.1093/ofid/ofaa461
  64. Sastre-Femenia M, Fernández-Muñoz A, Gomis-Font M, Taltavull B, López-Causapé C, Arca-Suárez J, et al. Pseudomonas aeruginosa Antibiotic Susceptibility Profiles, Genomic Epidemiology and Resistance Mechanisms: A Nation-Wide Five-Year Time Lapse Analysis. The Lancet Regional Health - Europe. 2023 Nov 1;34:100736. Available from: https://doi.org/10.1016/j.lanepe.2023.100736
  65. Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program. Diagnostic Microbiology and Infectious Disease. 2018;92(1):69–74. Available from: https://doi.org/10.1016/j.diagmicrobio.2018.04.012
  66. Sid Ahmed MA, Khan FA, Sultan AA, Söderquist B, Ibrahim EB, Jass J, et al. β-Lactamase-Mediated Resistance in MDR-Pseudomonas aeruginosa from Qatar. Vol. 9, Antimicrobial Resistance and Infection Control. 2020. Available from: https://doi.org/10.1186/s13756-020-00838-y
  67. Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Kidambi S, Davis SL, et al. Multidrug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections in the Intensive Care Unit: Prevalence and Risk Factors. Diagnostic microbiology and infectious disease. 2017 Sep;89(1):61–6. Available from: https://doi.org/10.1016/j.diagmicrobio.2017.06.009
  68. Lob S, Hackel M, Siddiqui F, Bauer KA, DeRyke CA, Young K, et al. Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020. Open Forum Infectious Diseases. 2022 Dec 1;9(Supplement_2):ofac492.1301. Available from: https://doi.org/10.1093/ofid/ofac492.1301
  69. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Nov;67(12):1803–14. Available from: https://doi.org/10.1093/cid/ciy378
  70. Pachori P, Gothalwal R, Gandhi P. Emergence of Antibiotic Resistance Pseudomonas aeruginosa in Intensive Care Unit: A Critical Review. Genes & Diseases. 2019;6(2):109–19. Available from: https://doi.org/10.1016/j.gendis.2019.04.001
  71. Setianingsih Y, Fadraersada J, Ibrahim A, Ramadhan AM. Pola Resistensi Bakteri terhadap Antibiotik pada Pasien Diabetic Foot di RSUD Abdul Wahab Sjahranie Samarinda Periode Agustus-Oktober 2016. Vol. 4, Prosiding Seminar Nasional Kefarmasian. 2016. p. 20–1

Last update:

No citation recorded.

Last update:

No citation recorded.